NervGen Posts Q3 2026 Results With C$80.1M Cash; Material Weakness Still Unremediated
NGEN sits 52% above its 52-week low of $1.28 on elevated volume (1.8× avg).
Summary
NervGen reported C$80.1M of cash at September 30, 2026, enough for at least 12 months of operations, alongside a C$6.41M quarterly net loss and a material weakness in financial controls that remains unremediated.
Key Events · Earnings and Guidance · NGEN
-
Q3 2026 Results Filed
Three-month net loss of C$6.41M (C$0.06 per share) versus C$4.72M in Q3 2025; nine-month net income of C$2.47M versus a C$17.7M loss a year earlier.
-
Cash Position Jumps to C$80.1M
Cash and cash equivalents rose from C$22.1M at December 31, 2025 to C$80.1M at September 30, 2026, mainly from the May 2026 offering's US$60.0M gross proceeds; management says this funds at least 12 months of operations.
-
Net Income Is Non-Cash Warrant Gain
The C$33.9M nine-month gain on warrant derivative remeasurement is a non-cash mark-to-market entry driven by share price and volatility inputs, not a cash inflow and not new dilution; the warrant derivative liability stands at C$34.6M.
-
Material Weakness Still Unremediated
The ICFR weakness in option and warrant valuation and share-issuance cost classification persisted at September 30, 2026, and the CEO and CFO concluded DC&P and ICFR were not effective; remediation includes a valuation methodology memo, an Accounting Manager hired October 5, 2026 and a Director of Contracts hired August 12, 2026.
Analysis · NGEN · Life Sciences
The first periodic report since the restatement puts hard numbers on the balance sheet: C$80.1M of cash at September 30, 2026, up from C$22.1M at year-end 2025 after the May 2026 offering raised US$60.0M gross. That cash, management says, funds operations for at least the next 12 months, removing near-term financing pressure while the Phase 3 RESTORE trial ramps up. Headline nine-month net income of C$2.47M is an accounting artifact, not profitability: it stems from a C$33.9M non-cash gain on remeasuring the US-dollar-denominated warrant derivative as the share price moved, and the quarter itself was a C$6.41M net loss as R&D spending nearly doubled to C$7.90M. The governance overhang is unresolved. The material weakness in option and warrant valuation and share-issuance cost classification that forced the restatement was still present at September 30, 2026, and the CEO and CFO concluded disclosure controls and ICFR were not effective. Remediation is underway with a documented valuation memo, a new Accounting Manager and a Director of Contracts, but management cannot say when it will be complete.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, NGEN was trading at $1.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $204.5M. The 52-week trading range was $1.28 to $6.30. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.